Spots Global Cancer Trial Database for adult
Every month we try and update this database with for adult cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Mild Hypofractionation With Proton Therapy or Intensity Modulated Radiation Therapy (IMRT) for Intermediate-Risk Prostate Cancer | NCT01352429 | Prostate Adenoc... | Proton Therapy IMRT | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies | NCT05846659 | Oligoprogressiv... | IMSA101 Immune checkpoi... PULSAR | 18 Years - | ImmuneSensor Therapeutics Inc. | |
| Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection | NCT05393505 | Neutropenic Fev... | Meropenem Injec... Levofloxacin Amoxicillin Cla... Antibiotic | 18 Years - | The University of Hong Kong | |
| Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia | NCT05356169 | Acute Myeloid L... | with or without... | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer | NCT03706573 | HR+ Advanced or... | alpelisib | 18 Years - | Novartis | |
| Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation | NCT02411019 | Cervical Intrae... | GX-188E | 19 Years - 50 Years | Genexine, Inc. | |
| Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC | NCT05846646 | Oligometastatic... | IMSA101 Immune checkpoi... PULSAR | 18 Years - | ImmuneSensor Therapeutics Inc. | |
| An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. | NCT01582061 | Cushing's Disea... | Pasireotide sub... | 18 Years - | Novartis | |
| Adult ALL Treatment at Diagnosis | NCT00537550 | Leukemia, Lymph... | Vincristine Vincristin, Dau... | 14 Years - 60 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia | NCT00376467 | Acute Lymphobla... | Imatinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies | NCT01435447 | Lymphoid Malign... | FLu-Bu-Cy | 16 Years - 60 Years | Shanghai Jiao Tong University School of Medicine | |
| End-of-life Communication From a Chinese Perspective | NCT05734781 | Terminally Ill | Not Application... | 18 Years - | The Hong Kong Polytechnic University | |
| The Relationship Between Fat Free Mass and Toxicity of Cytostatics in Cancer Patients | NCT04528745 | Pancreas Cancer Colorectal Canc... | Bio Impedance S... | 18 Years - | University of Copenhagen | |
| Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. | NCT02292446 | Polycythemia Ve... | Ruxolitinib | 18 Years - | Novartis | |
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | NCT00495079 | Acute Lymphobla... | Marqibo® (vincr... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Molecular Diagnostic Platform for AML | NCT04446741 | Acute Myeloid L... | 18 Years - 99 Years | PETHEMA Foundation | ||
| End-of-life Communication From a Chinese Perspective | NCT05734781 | Terminally Ill | Not Application... | 18 Years - | The Hong Kong Polytechnic University | |
| Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation | NCT02411019 | Cervical Intrae... | GX-188E | 19 Years - 50 Years | Genexine, Inc. | |
| A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting | NCT02041260 | Differentiated ... Poorly Differen... | Cabozantinib | 18 Years - | Thomas Jefferson University | |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. | NCT05770544 | Solid Tumor Haematological ... Malignancy Malignant Neopl... Lymphoprolifera... Neoplasms by Hi... Neoplasms by Si... Cancer Brain Neoplasms Melanoma Glioma | Entrectinib | - | Cancer Research UK | |
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | NCT00495079 | Acute Lymphobla... | Marqibo® (vincr... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| IDH1 Peptide Vaccine for Recurrent Grade II Glioma | NCT02193347 | Brain Cancer Brain Neoplasm,... Brain Neoplasms... Brain Tumor Cancer of the B... | PEPIDH1M vaccin... Tetanus-Diphthe... Temozolomide | 18 Years - | Duke University | |
| CTL019 Out of Specification MAP for ALL or DLBCL Patients | NCT03601442 | Acute Lymphobla... Diffuse Large B... | CTL019 | 1 Day - 25 Years | Novartis | |
| Gender Related Coping and Survivorship for Genitourinary Cancers | NCT05649306 | Bladder Cancer | Additional Educ... Questionnaires Attendance Diar... | 18 Years - | Johns Hopkins University | |
| Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML) | NCT00822094 | Acute Myeloid L... | CPX-351 Intensive Salva... | 18 Years - 65 Years | Jazz Pharmaceuticals | |
| Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults | NCT04179929 | Acute Lymphobla... | Pediatric-type ... allogeneic HSCT | 18 Years - 60 Years | PETHEMA Foundation | |
| Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. | NCT05049473 | Mature B-Cell L... Burkitt Lymphom... Unclassifiable ... | Rituximab Methotrexate Dexamethasone Iphosphamid Vincristine Etoposide Cytarabine Cyclophosphamid... Doxorubicin Vindesine Cytarabine Methotrexate Hydrocortisone Prednisone | 18 Years - | PETHEMA Foundation | |
| Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3 | NCT01634503 | Cervical Intrae... | GX-188E adminis... | 20 Years - 50 Years | Genexine, Inc. | |
| Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy | NCT05064787 | Lymphoma Lymphoma, B-Cel... Leukemia Multiple Myelom... Mantle Cell Lym... Follicular Lymp... Leukemia, Acute... | Digital Health ... | 18 Years - | Pack Health | |
| Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer | NCT03706573 | HR+ Advanced or... | alpelisib | 18 Years - | Novartis | |
| LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors | NCT00052273 | Adult Solid Tumor | capecitabine enzastaurin hyd... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| ComCancer: Use of Let's Discuss Health Website by Patients With Prostate Cancer Undergoing Radiation Oncology Treatment | NCT05787145 | Prostatic Neopl... Psychological D... Physician-Patie... Communication Patient Partici... Adherence, Trea... Men | Let's Discuss H... | 18 Years - | Ciusss de L'Est de l'Île de Montréal | |
| Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes | NCT00809575 | Adult Myelodysplastic... | questionnaire a... fatigue assessm... observation quality-of-life... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors | NCT06094426 | Solid Tumor Adult GT316 | GT316 | 18 Years - 70 Years | Grit Biotechnology | |
| A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589 | NCT00472368 | Cancer Patients... | LBH589 | 18 Years - | Novartis | |
| A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall | NCT00790244 | Soft Tissue Sar... Non Metastatic ... | doxorubicin , i... doxorubicin, if... doxorubicin, if... doxorubicin, if... | 18 Years - 75 Years | Oslo University Hospital | |
| A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. | NCT01743989 | Philadelphia Ch... | Nilotinib | 18 Years - | Novartis | |
| GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer | NCT06235242 | Adult Non-small Cell ... | GT201 injection... | 18 Years - 70 Years | Grit Biotechnology | |
| Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase | NCT00481052 | Chronic Myeloid... | Nilotinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC) | NCT04792567 | Secondary Progr... | BAF312 Baseline diseas... BNT162 mRNA-1273 | 18 Years - 100 Years | Novartis | |
| Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer | NCT06241781 | Adult | GT101 injection Gemcitabine inj... | 18 Years - 70 Years | Grit Biotechnology | |
| Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia | NCT05356169 | Acute Myeloid L... | with or without... | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple | NCT02976272 | Multiple Myelom... Bortezomib Regi... Adult | bortezomib | 18 Years - | University Hospital, Clermont-Ferrand | |
| Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) | NCT05445778 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | Mirvetuximab so... Bevacizumab | 18 Years - | ImmunoGen, Inc. | |
| STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS | NCT04878432 | Myelodysplastic... | MBG453 Azacitidine Decitabine INQOVI (oral de... | 18 Years - 99 Years | Novartis | |
| Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple | NCT02976272 | Multiple Myelom... Bortezomib Regi... Adult | bortezomib | 18 Years - | University Hospital, Clermont-Ferrand | |
| The NutriNet-Santé Study | NCT03335644 | Diet, Food, and... Exercise Diseases Catego... Cohort Studies Adult Anthropometry Humans Internet Surveys and Que... Mortality | 15 Years - | University of Paris 13 | ||
| Mindfully Optimizing Delivery of End-of-Life Care | NCT02367508 | Cancer Coping Skills | MODEL Care | 18 Years - | Indiana University | |
| Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies | NCT05846659 | Oligoprogressiv... | IMSA101 Immune checkpoi... PULSAR | 18 Years - | ImmuneSensor Therapeutics Inc. | |
| Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer) | NCT06191900 | Adult Gynecological T... | Autologous tumo... | 18 Years - 70 Years | Grit Biotechnology | |
| Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel | NCT05199961 | Lymphoma, Large... | Digital Health ... | 18 Years - 90 Years | Pack Health | |
| Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | NCT00664677 | Leukemias Acute Myeloid L... Acute Lymphocyt... Adult T Cell Le... Chronic Myeloid... Chronic Lymphoc... Myelodysplastic... Chronic Myelomo... | Terameprocol (E... | 18 Years - | Erimos Pharmaceuticals | |
| Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia | NCT00021749 | Chronic Lymphoc... CLL | Oblimerson sodi... | 18 Years - | Genta Incorporated | |
| Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia | NCT00078234 | Chronic Lymphoc... | Oblimersen-ritu... | 18 Years - | Genta Incorporated | |
| Individual Dose-escalated Bi-daily Subcutaneously (sc) Ghrelin in Cancer Cachexia: a Phase I/II Study | NCT00933361 | Advanced Cancer Cachexia | ghrelin | 18 Years - | Cantonal Hospital of St. Gallen | |
| Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer | NCT01220128 | Neoplasms, Brea... | GSK Biologicals... Placebo Aromatase inhib... 5-Fluorouracil Carboplatin AUC Cyclophosphamid... Docetaxel Doxorubicin Epirubicin Paclitaxel Trastuzumab | 18 Years - | GlaxoSmithKline | |
| Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation | NCT02100085 | Cervical Intrae... | GX-188E | 20 Years - 50 Years | Genexine, Inc. | |
| An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML) | NCT03114228 | FLT3-mutated Ac... | Midostaurin | 18 Years - | Novartis | |
| Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan | NCT00742105 | Cancer Solid Tumor Advanced Solid ... | BGT226 | 20 Years - | Novartis | |
| Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | NCT03318770 | Acute Lymphobla... | Dasatinib and b... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Genotyping Analysis of Acute Lymphoblastic Leukemia | NCT00961285 | Acute Lymphobla... Adult | 18 Years - | University of Bologna | ||
| A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) | NCT04590235 | Neurofibromatos... Neurofibroma Pl... | Selumetinib | 3 Years - 99 Years | AstraZeneca | |
| Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML | NCT01883362 | Acute Myeloid L... | Midostaurin Standard of Car... | 18 Years - 70 Years | Novartis | |
| A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) | NCT04573140 | Adult Glioblast... | Autologous tota... | 21 Years - | University of Florida | |
| Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | NCT02078648 | Adult Brain Gli... Glioblastoma Mu... | SL-701; poly-IC... Bevacizumab SL-701 + GM-CSF Imiquimod | 18 Years - | Stemline Therapeutics, Inc. | |
| A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) | NCT04573140 | Adult Glioblast... | Autologous tota... | 21 Years - | University of Florida | |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. | NCT05768178 | Solid Tumor Haematological ... Melanoma Thyroid Cancer,... Ovarian Neoplas... Colorectal Neop... Laryngeal Neopl... Carcinoma, Non-... Glioma Multiple Myelom... Erdheim-Chester... Thyroid Carcino... | Vemurafenib Cobimetinib | 18 Years - | Cancer Research UK | |
| Evaluating Procedures for a Study of the AYA Survivors Coping and Emotional Needs Toolkit | NCT06420193 | Depression Cancer Adolescent Young Adult Adult | AYA Survivors C... | 15 Years - 39 Years | East Carolina University | |
| Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM | NCT03283631 | Recurrent Gliob... Recurrent Glios... | EGFRvIII-CARs | 18 Years - | Duke University | |
| IDH1 Peptide Vaccine for Recurrent Grade II Glioma | NCT02193347 | Brain Cancer Brain Neoplasm,... Brain Neoplasms... Brain Tumor Cancer of the B... | PEPIDH1M vaccin... Tetanus-Diphthe... Temozolomide | 18 Years - | Duke University | |
| The NutriNet-Santé Study | NCT03335644 | Diet, Food, and... Exercise Diseases Catego... Cohort Studies Adult Anthropometry Humans Internet Surveys and Que... Mortality | 15 Years - | University of Paris 13 | ||
| Mild Hypofractionation With Proton Therapy or Intensity Modulated Radiation Therapy (IMRT) for Intermediate-Risk Prostate Cancer | NCT01352429 | Prostate Adenoc... | Proton Therapy IMRT | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Genotyping Analysis of Acute Lymphoblastic Leukemia | NCT00961285 | Acute Lymphobla... Adult | 18 Years - | University of Bologna | ||
| Individual Dose-escalated Bi-daily Subcutaneously (sc) Ghrelin in Cancer Cachexia: a Phase I/II Study | NCT00933361 | Advanced Cancer Cachexia | ghrelin | 18 Years - | Cantonal Hospital of St. Gallen | |
| Adult ALL Treatment at Diagnosis | NCT00537550 | Leukemia, Lymph... | Vincristine Vincristin, Dau... | 14 Years - 60 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia | NCT00376467 | Acute Lymphobla... | Imatinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Gender Related Coping and Survivorship for Genitourinary Cancers | NCT05649306 | Bladder Cancer | Additional Educ... Questionnaires Attendance Diar... | 18 Years - | Johns Hopkins University | |
| Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation | NCT04666259 | Chronic Myeloge... | ABL001 | 18 Years - | Novartis | |
| Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults | NCT04179929 | Acute Lymphobla... | Pediatric-type ... allogeneic HSCT | 18 Years - 60 Years | PETHEMA Foundation | |
| Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation | NCT01086735 | Hematological M... | donor lymphocyt... | 18 Years - 70 Years | Assistance Publique - Hôpitaux de Paris |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
